Atlas Trials

Refractory Mixed Phenotype Acute Leukemia

10 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Refractory Mixed Phenotype Acute Leukemia

RecordFirmDate
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms (NCT04797767)University of Washington2022-02-04
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia (NCT04375631)Fred Hutchinson Cancer Center2020-12-03
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome (NCT03670966)Fred Hutchinson Cancer Center2019-07-10
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome (NCT03404193)M.D. Anderson Cancer Center2018-01-18
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia (NCT02879695)National Cancer Institute (NCI)2017-10-25
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia (NCT03128034)Fred Hutchinson Cancer Center2017-10-24

Track Refractory Mixed Phenotype Acute Leukemia automatically

Every clearance here is in the API, with alerts when new ones post.